Proteasome inhibition represents a new anticancer approach, with the potential effect of arresting tumor growth, metastasis and angiogenesis through the activation of multiple mechanisms. Bortezomib is a biologically active agent, producing predictable, dose-related and reversible proteasome inhibition; it has shown antitumor activity in various malignancies and is the first proteasome inhibitor to be used in clinical practice. Several trials demonstrated that bortezomib is relatively well tolerated, causing manageable nonhematologic and hematologic toxicity. The drug was approved in 2003 by the FDA for the treatment of patients with multiple myeloma who had received at least two prior therapies and demonstrated disease progression on the last therapy; its application was expanded recently for second-line treatment. This article summarizes the principal clinical trials of bortezomib and discusses its efficacy in solid and hematologic tumors. © 2006 Nature Publishing Group.

Caravita, T., DE FABRITIIS, P., Palumbo, A., Amadori, S., Boccadoro, M. (2006). Bortezomib: Efficacy comparisons in solid tumors and hematologic malignancies. NATURE CLINICAL PRACTICE ONCOLOGY, 3(7), 374-387 [10.1038/ncponc0555].

Bortezomib: Efficacy comparisons in solid tumors and hematologic malignancies

DE FABRITIIS, PAOLO;AMADORI, SERGIO;
2006-01-01

Abstract

Proteasome inhibition represents a new anticancer approach, with the potential effect of arresting tumor growth, metastasis and angiogenesis through the activation of multiple mechanisms. Bortezomib is a biologically active agent, producing predictable, dose-related and reversible proteasome inhibition; it has shown antitumor activity in various malignancies and is the first proteasome inhibitor to be used in clinical practice. Several trials demonstrated that bortezomib is relatively well tolerated, causing manageable nonhematologic and hematologic toxicity. The drug was approved in 2003 by the FDA for the treatment of patients with multiple myeloma who had received at least two prior therapies and demonstrated disease progression on the last therapy; its application was expanded recently for second-line treatment. This article summarizes the principal clinical trials of bortezomib and discusses its efficacy in solid and hematologic tumors. © 2006 Nature Publishing Group.
2006
Pubblicato
Rilevanza internazionale
Articolo
Sì, ma tipo non specificato
Settore MED/15 - MALATTIE DEL SANGUE
English
Bortezomib; Hematologic malignancies; Proteasome inhibition; Solid tumors
Caravita, T., DE FABRITIIS, P., Palumbo, A., Amadori, S., Boccadoro, M. (2006). Bortezomib: Efficacy comparisons in solid tumors and hematologic malignancies. NATURE CLINICAL PRACTICE ONCOLOGY, 3(7), 374-387 [10.1038/ncponc0555].
Caravita, T; DE FABRITIIS, P; Palumbo, A; Amadori, S; Boccadoro, M
Articolo su rivista
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/43089
Citazioni
  • ???jsp.display-item.citation.pmc??? 43
  • Scopus ND
  • ???jsp.display-item.citation.isi??? 100
social impact